Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

Presentation EuroPCR 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presenter: Alexandre Abizaid

May 14, 2024

Presentation EuroPCR 2023

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Presenter: Shigeru Saito

May 18, 2023

Presentation EuroPCR 2023

The European Bifurcation Club Left Main Coronary Stent study - a randomised comparison of stepwise provisional versus systematic dual stenting strategies (EBC MAIN): 3 year results

Presenter: David Hildick-Smith

May 16, 2023

Presentation EuroPCR 2022

The ROLEX Study(Revascularization Of LEft main with resolute onyX): A prospective, international, multicenter study of left main PCI with a zotarolimus-eluting stent

Presenter: Giuseppe Tarantini

May 31, 2022

Presentation EuroPCR 2019

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Presenter: Clemens von Birgelen

May 21, 2019

Presentation EuroPCR 2019

Drug-coated Balloons vs. Drug-eluting Stents for the Treatment of Small Coronary Artery Lesions: Angiographic Analysis from the Randomised BASKET-SMALL 2 Trial

Presenter: Raban Jeger

May 20, 2019

Presentation EuroPCR 2018

TARGET AC A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent

Presenter: Andreas Baumbach

May 25, 2018

Presentation EuroPCR 2017

First Report of a 2.0 mm ZotarolimusEluting Stent for the Treatment of Very Small Coronary Vessels

Presenter: Matthew J. Price

May 19, 2017

Presentation EuroPCR 2017

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Presenter: Runlin Gao

May 17, 2017

Presentation EuroPCR 2016

Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a LEADERS FREE ACS substudy

Presenter: Christoph Naber

May 19, 2016

Presentation EuroPCR 2016

Sealing Moderate Coronary Saphenous Vein Graft Lesions with Drug-Eluting Stents as a New Approach to Reducing Cardiac Events The VELETI II Randomized Trial

Presenter: Josep Rod?s-Cabau

May 19, 2016

Presentation EuroPCR 2015

ILUMIEN II: A Retrospective Evaluation of Stent Expansion with OCT Guidance vs IVUS Guidance

Presenter: Gregg Stone

May 22, 2015

Presentation EuroPCR 2015

Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately 8000 Patients

Presenter: Sigmund Silber

May 19, 2015

Presentation EuroPCR 2014

Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial

Presenter: Stephan Windecker

May 22, 2014

Presentation EuroPCR 2014

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

Presenter: Hiroyoshi Yokoi

May 21, 2014

Presentation EuroPCR 2013

Two-year clinical outcomes in the EVOLVE FHU trial:A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Presenter: 203171|Ian Meredith

May 31, 2013

Presentation EuroPCR 2013

One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study

Presenter: 13956|Raul Moreno

May 31, 2013

Presentation EuroPCR 2013

Clinical, Angiographic and IVUS Outcomes of the NG PROMUS Clinical Trial Evaluating the Novel Promus PREMIER Stent

Presenter: 228635|John Ormiston

May 31, 2013

Presentation EuroPCR 2013

First-in-man study of dedicated bifurcation sirolimus-eluting stent BiOSS LIM® – complete 6-month clinical results

Presenter: Robert J. Gil

May 22, 2013

Presentation EuroPCR 2012

APPOSITION III: Evaluation of the STENTYS self-apposing bare and drug-eluting stent in 1000 STEMI patients in a real-life setting: in-hospital and 30-day outcomes

Presenter: 166648|giovanni amoroso

May 18, 2012

Advertisement

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

The European Bifurcation Club Left Main Coronary Stent study - a randomised comparison of stepwise provisional versus systematic dual stenting strategies (EBC MAIN): 3 year results

The ROLEX Study(Revascularization Of LEft main with resolute onyX): A prospective, international, multicenter study of left main PCI with a zotarolimus-eluting stent

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Drug-coated Balloons vs. Drug-eluting Stents for the Treatment of Small Coronary Artery Lesions: Angiographic Analysis from the Randomised BASKET-SMALL 2 Trial

TARGET AC A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent

First Report of a 2.0 mm ZotarolimusEluting Stent for the Treatment of Very Small Coronary Vessels

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a LEADERS FREE ACS substudy

Sealing Moderate Coronary Saphenous Vein Graft Lesions with Drug-Eluting Stents as a New Approach to Reducing Cardiac Events The VELETI II Randomized Trial

ILUMIEN II: A Retrospective Evaluation of Stent Expansion with OCT Guidance vs IVUS Guidance

Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately 8000 Patients

Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

Two-year clinical outcomes in the EVOLVE FHU trial:A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study

Clinical, Angiographic and IVUS Outcomes of the NG PROMUS Clinical Trial Evaluating the Novel Promus PREMIER Stent

First-in-man study of dedicated bifurcation sirolimus-eluting stent BiOSS LIM® – complete 6-month clinical results

APPOSITION III: Evaluation of the STENTYS self-apposing bare and drug-eluting stent in 1000 STEMI patients in a real-life setting: in-hospital and 30-day outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content